.jpg?w=340&itok=AZLofY9I "EPR in healthcare news."){kind=icon}
From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Standing out in a crowded precision oncology landscape
A 2024 ICON survey of over 100 oncology developers’ pipelines reflected a diverse and highly complex landscape of emerging precision oncology therapies. These emerging therapies in oncology are displacing traditional toxic treatments such as chemotherapy and radiation.
-
Advances in imaging biomarkers: Estimating efficacy with tumour growth rate modelling
Imaging biomarkers are an essential part of oncology trials, tracking the efficacy of the new treatment and comparing it to the existing gold standard therapies. The insights gleaned from imaging biomarkers steer the course of oncology clinical trials, informing decision-making and endpoints. This article discusses the benefits of tumour growth rate modelling.
-
Oncology R&D: emerging therapies and new challenges
Worldwide demand for cancer therapies is set to soar – and biomanufacturers are in the spotlight. Explore emerging industry data to distinguish trends and prepare for the future of oncology.
-
To be precise: How oncology therapies can stand out in a diverse, uncertain landscape
Targeted product profiles and biomarkers for patient screening are essential elements of success for oncology treatment developers, according to our recent survey. This article explores why both prove challenging for drug developers.
-
Strategies for commercialising oncology treatments for young adults
This article explores the imperatives and strategies for commercialising oncology treatments targeting young adults, highlighting the need for innovative regulatory and commercial strategies to ensure successful market entry and improved patient outcomes.
-
Survey shows varied views on impact of new cancer drugs
This article published in The Pharma Letter highlights findings from an ICON survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
-
Innovation and flexibility in long-term follow-up studies
Read insights from Harpreet Gill VP, Real World Solutions, on how sponsors can optimise their LTFU studies to be flexible and cost-effective, with strategic planning and innovation, overcoming challenges while capturing valuable data insights.
-
Biomarker Identification a Challenge and Opportunity in Cancer Drug Development, Survey Finds
This news piece from Precision Medicine Online provides an overview of the findings from ICON’s recent survey of professionals engaged in oncology-related clinical research. It shares respondents' insights on how precision medicine approaches are changing development strategies and the to the extent these therapeutic advances will benefit patients in the future.
-
Overcoming Challenges in the Development of Antibody Drug Conjugates
In this article, ICON’s Andreas Dreps reviews the innovations that have helped ADCs overcome clinical development challenges.
-
7c45.jpg "EPR in healthcare news.")
Application of NGS to enhance the molecular monitoring of CML patients
This Q&A with Dr Jin Li and Dr Chad Galderisi of ICON Specialty Laboratory Solutions discusses ICON’s development of its RNA-based next generation sequencing (NGS) assay that detects mutations in chronic myeloid leukemia (CML) and how it can benefit both routine clinics and clinical trial settings.
